Short Interest in Estrella Immunopharma, Inc. (NASDAQ:ESLA) Decreases By 95.6%

Estrella Immunopharma, Inc. (NASDAQ:ESLA) was the recipient of a large drop in short interest in October. As of October 15th, there was short interest totalling 15,100 shares, a drop of 95.6% from the September 30th total of 346,200 shares. Approximately 0.2% of the shares of the stock are short sold. Based on an average trading volume of 196,600 shares, the short-interest ratio is presently 0.1 days.

Estrella Immunopharma Stock Performance

Estrella Immunopharma stock traded up $0.05 during mid-day trading on Friday, hitting $0.90. 4,190 shares of the company traded hands, compared to its average volume of 82,161. The stock has a fifty day moving average price of $1.05 and a 200-day moving average price of $1.12. The stock has a market cap of $32.74 million, a price-to-earnings ratio of -0.46 and a beta of 0.18. Estrella Immunopharma has a one year low of $0.77 and a one year high of $3.23.

Estrella Immunopharma (NASDAQ:ESLA) last announced its earnings results on Friday, September 27th. The company reported ($0.13) earnings per share (EPS) for the quarter.

About Estrella Immunopharma

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia.